VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 28346412.
- Also identified by DOI 10.1038/nm.4308 and PMC identifier 5466900.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To date, anti-CTLA-4 (ipilimumab) or anti-PD-1 (nivolumab) monotherapy has not been demonstrated to be of substantial clinical benefit in patients with prostate cancer. To identify additional immune-inhibitory pathways in the prostate-tumor microenvironment, we evaluated untreated and ipilimumab-treated tumors from patients in a presurgical clinical trial. Levels of the PD-L1 and VISTA inhibitory molecules increased on independent subsets of macrophages in treated tumors. Our data suggest that VISTA represents another compensatory inhibitory pathway in prostate tumors after ipilimumab therapy.
Medical subject headings
- Adenocarcinoma
- Antibodies, Monoclonal
- Antineoplastic Agents
- B7 Antigens
- B7-H1 Antigen
- Macrophages
- Prostatic Neoplasms